Astellas partners with Adaptimmune in latest move into cell therapy
The companies will work to develop allogeneic CAR-T and T-cell receptor therapies. Astellas has made multiple moves into cell and gene therapy in the past month.
Astellas buys Xyphos – and its cell therapy platform – for $665M
The deal comes less than a month after the Japanese drugmaker said it would spend $3 billion to acquire gene therapy developer Audentes Therapeutics.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Astellas dives into gene therapy with $3B acquisition of Audentes Therapeutics
Shares of Audentes rose more than 100% following news that the Japanese drugmaker would acquire it. The company's lead candidate is a gene therapy for a rare muscular weakness disorder, currently in a Phase I/II study for which it presented data in October.
Concerto HealthAI, Astellas partner on RWE in acute myeloid leukemia
The partnership will focus on using real-world evidence to improve understanding of responses among patients with acute myeloid leukemia whose disease carries mutations in the FLT3 gene. Astellas markets a drug for FLT3-positive AML, Xospata, approved in November.
Astellas’s Xospata in AML scores a goal with new Phase III survival data at AACR
The drug was approved for FLT3-mutated acute myeloid leukemia in November based on response rate data, but the latest results show improvement on the gold-standard measure of overall survival.
FDA approves Astellas’ Xospata for FLT3-mutated acute myeloid leukemia
The drug is the second FLT3 inhibitor to win approval, after Novartis' Rydapt in first-line disease. Daiichi Sankyo's quizartinib could present competition if it wins approval, but it would target a somewhat narrower population of FLT3-mutated patients.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Former Lumiata COO leads pharma-backed investment firm targeting digital health startups
DigiTx Partners CEO Dr. David Kim talks strategy, targets and the firm's backing from Astellas Pharma and MPM Capital.